Akamis Bio is a clinical-stage oncology company dedicated to improving the lives of cancer patients through innovative gene therapies. The company utilizes its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to develop therapeutics specifically targeting solid tumors. By employing an intravenously administered virus, Akamis Bio aims to enhance the immune system's ability to recognize, attack, and eliminate cancer cells. Through its focused approach to immunobiology treatments, the company seeks to provide effective solutions for patients battling cancer.
Hybrid BioSystems develops gene therapy treatments for ovarian and prostate cancer. It exploits the interface between polymer chemistry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.